Targeting the Wnt pathway could therefore be an interesting new avenue to treat MM: (1) it could increase apoptosis of MM cells and thereby decrease tumor growth; (2) it could reduce Dkk1 levels secreted by MM cells and thereby reduce osteolytic bone disease and subsequent bone-related symptoms; (3) it could reduce MM acquired CAM-DR and thereby increase the response to established treatment regimens. The gene discussed is DKK1; the disease is Miyoshi myopathy.